Physician profile
Jasmin Ray
NPI 1649084203
$3,759.55
in general payments reported to CMS, 2019-2025
25 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878 · Travel and Lodging: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.44 |
| Travel and Lodging | $881.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,141.95 | 2025 | Vns Therapy |
| Ucb, INC. | $833.28 | 2025 | Fintepla, Briviact, Nayzilam |
| Sk Life Science, INC. | $252.40 | 2025 | Xcopri |
| Neurelis, INC. | $221.53 | 2025 | Valtoco |
| Abbvie INC. | $198.79 | 2025 | |
| Corium, LLC | $109.92 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $108.41 | 2025 | Symbravo |
| Harmony Biosciences LLC | $87.64 | 2025 | |
| Acadia Pharmaceuticals INC | $87.62 | 2025 | Daybue |
| Collegium Pharmaceutical, INC. | $86.07 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $72.92 | 2025 | Xelstrym |
| Jazz Pharmaceuticals INC. | $67.32 | 2025 | |
| Janssen Biotech, INC. | $53.91 | 2025 | |
| Neurocrine Biosciences, INC. | $53.01 | 2025 | |
| Tris Pharma INC | $51.23 | 2025 | Dyanavel Xr, Onyda Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $50.29 | 2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $49.08 | 2025 | |
| Csl Behring | $48.52 | 2025 | Hizentra |
| Intrabio INC | $43.39 | 2025 | Aqneursa |
| Biogen, INC. | $29.04 | 2025 | Spinraza |
| Azurity Pharmaceuticals, INC. | $28.06 | 2025 | Zonisade |
| Teva Pharmaceuticals USA, INC. | $26.24 | 2025 | Ajovy |
| Catalyst Pharmaceuticals, INC. | $24.93 | 2025 | |
| Forte Bio-Pharma LLC | $17.58 | 2025 | Tanlor |
| Neos Therapeutics, LP | $16.42 | 2025 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.